Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Eli Lilly to invest $6 billion in new synthetic medicine facility in Huntsville, AL to boost domestic production and create ...

Policy swings have made it a slippery year for pharma ...

Candidate selection underscores Confo’s ability to rapidly advance differentiated GPCR-targeting therapeutics and its focus on metabolic and ...

Meanwhile, people with overweight or obesity lost up to 11.3% more weight than placebo by week 36 with a novel GLP-1 agonist ...

"Eli Lilly picks Alabama as home to $6bn orforglipron manufacturing facility" was originally created and published by ...

The other experimental drug is bimagrumab, which is designed to help patients on weight loss medications from losing too much ...

Research suggests certain medications could help build or maintain muscle during weight loss. Here's how they work & how to ...

Siemens Healthineers has tapped the Alzheimer’s disease blood test developer ALZpath for an in vitro diagnostic to ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

Ability Biotherapeutics, a biotechnology company advancing logic-gated antibody therapies for cancer and autoimmune diseases, today announced the appointment of Angèle Maki, PhD, as Chief Business ...

In this week’s edition of InnovationRx, we look at French healthtech Doctolib’s potential large secondary round, Alice ...